Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to increase following the approval of additional therapies, such as Pfizer’s Vizimpro for first-line EGFR-mutation-positive NSCLC and Astra Zeneca’s Imfinzi for unresectable Stage III NSCLC. Label expansions of existing treatments to earlier settings will also fuel costs, such as Merck & Co.'s Keytruda in first-line metastatic squamous NSCLC and unresectable Stage III NSCLC. As therapies seek to optimize their place in clinical practice, and EU5 markets strive to constrain healthcare expenditures, payers and prescribers must balance tightening budgets and evolving cost-containment policies with clinical need.
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers to examine reimbursement dynamics and evaluate the impact of payer policy on prescribing behavior.
France, Germany, Italy, Spain, and United Kingdom
KEY DRUGS COVERED
Keytruda, Opdivo, Tecentriq, Imfinzi, Tagrisso, Tafinlar, Mekinist, Vizimpro, Tarceva, Zykadia, Xalkori, Alunbrig, Alecensa, Avastin, Abraxane, Alimta, Giotrif, Cyramza